{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T22:29:11Z","timestamp":1775082551535,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2006,6,1]],"date-time":"2006-06-01T00:00:00Z","timestamp":1149120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2006,6]]},"DOI":"10.1016\/j.clinthera.2006.06.008","type":"journal-article","created":{"date-parts":[[2006,7,21]],"date-time":"2006-07-21T18:20:53Z","timestamp":1153506053000},"page":"881-892","source":"Crossref","is-referenced-by-count":21,"title":["A double-blind, randomized trial to evaluate the pharmacokinetics and tolerability of 30 or 40 mg\/d oral olanzapine relative to 20 mg\/d oral olanzapine in stable psychiatric subjects"],"prefix":"10.1016","volume":"28","author":[{"given":"Malcolm","family":"Mitchell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Riesenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad A.","family":"Bari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darcie","family":"Kurtz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deborah","family":"Falk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy C.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Cavazzoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2006.06.008_bib1","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2165\/00003088-199937030-00001","article-title":"Olanzapine. Pharmacokinetic and pharmacodynamic profile","volume":"37","author":"Callaghan","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 10","key":"10.1016\/j.clinthera.2006.06.008_bib2","first-page":"13","article-title":"Safety of olanzapine","volume":"58","author":"Beasley","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1080\/10673220216279","article-title":"Optimal dosing of atypical antipsychotics in adults: A review of the current evidence","volume":"10","author":"Citrome","year":"2002","journal-title":"Harv Rev Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2174\/0929867043456070","article-title":"A critical review of atypical antipsychotic utilization: Comparing monotherapy with polypharmacy and augmentation","volume":"11","author":"Stahl","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.clinthera.2006.06.008_bib5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1176\/ajp.154.11.1626","article-title":"High-dose olanzapine for treatment-refractory schizophrenia","volume":"154","author":"Sheitman","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/00004714-199906000-00015","article-title":"Schizophrenia and schizoaffective disorder treated with high doses of olanzapine","volume":"19","author":"Fanous","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib7","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1176\/ajp.156.1.158a","article-title":"British experience with high-dose olanzapine for treatment-refractory schizophrenia","volume":"156","author":"Mountjoy","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib8","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1176\/ajp.156.4.661","article-title":"Use of high-dose olanzapine in refractory psychosis","volume":"156","author":"Reich","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00002826-200303000-00003","article-title":"High-dose olanzapine for treatment-refractory schizophrenia","volume":"26","author":"Lerner","year":"2003","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1177\/070674379904400709","article-title":"Olanzapine for patients with treatment-resistant schizophrenia: A naturalistic case-series outcome study","volume":"44","author":"Dursun","year":"1999","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.159.2.255","article-title":"Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective dis order","volume":"159","author":"Volavka","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3109\/10401230309085687","article-title":"Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia","volume":"15","author":"Kelly","year":"2003","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib13","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.4088\/JCP.v64n1008","article-title":"High-dose olanzapine and prolactin levels","volume":"64","author":"Karagianis","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib14","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib15","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-200006000-00017","article-title":"Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia","volume":"20","author":"Bronson","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/appi.ajp.160.2.290","article-title":"Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics","volume":"160","author":"Lindenmayer","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib17","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1176\/appi.psy.44.2.174","article-title":"QTc prolongation and high-dose olanzapine","volume":"44","author":"Dineen","year":"2003","journal-title":"Psychosomatics"},{"key":"10.1016\/j.clinthera.2006.06.008_bib18","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1177\/026988110201600213","article-title":"A possible association between high normal and high dose olanzapine and prolongation of the PR interval","volume":"16","author":"Kosky","year":"2002","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib19","series-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000"},{"key":"10.1016\/j.clinthera.2006.06.008_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0378-4347(95)00061-M","article-title":"Analysis of olanzapine in human plasma utilizing reversed-phase highperformance liquid chromatography with electrochemical detection","volume":"668","author":"Catlow","year":"1995","journal-title":"J Chromatogr B Biomed Appl"},{"key":"10.1016\/j.clinthera.2006.06.008_bib21","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/0893-133X(95)00069-P","article-title":"Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial","volume":"14","author":"Beasley","year":"1996","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4088\/JCP.v62n0204","article-title":"Longterm olanzapine treatment: Weight change and weight-related health factors in schizophrenia","volume":"62","author":"Kinon","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib23","doi-asserted-by":"crossref","first-page":"931","DOI":"10.4088\/JCP.v63n1011","article-title":"Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: An open-label switch study","volume":"63","author":"Lindenmayer","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib24","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4088\/JCP.v62n0404","article-title":"Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone","volume":"62","author":"Basson","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.clinthera.2006.06.008_bib25","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/00004714-200206000-00003","article-title":"Antipsychoticinduced weight gain and therapeutic response: A differential association","volume":"22","author":"Czobor","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/01.jcp.0000162800.64378.82","article-title":"The association of weight gain and olanzapine plasma concentrations","volume":"25","author":"Perry","year":"2005","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.clinthera.2006.06.008_bib27","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1177\/0269881103174013","article-title":"The Barnes Akathisia Rating Scale-revisited","volume":"17","author":"Barnes","year":"2003","journal-title":"J Psychopharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001445?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291806001445?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T05:24:28Z","timestamp":1683523468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291806001445"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["S0149291806001445"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2006.06.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2006,6]]}}}